Change of strategy for AstraZeneca. The Anglo-Swedish pharmaceutical giant has decided to benefit from the anti-Covid vaccine it developed with the University of Oxford. Unlike its rivals, the group had pledged to sell its serum - one of the first to market with Pfizer - at cost during the pandemic. In the future, only developing countries will continue to buy it at this price. AstraZeneca will
"gradually make a transition from the vaccine to modest profitability as new orders are received,"
the group said on Friday.
"We want our vaccine to remain affordable for developing countries",
detailed the French Pascal Soriot, managing director of AstraZeneca.
And the benefits the laboratory expects to derive from the vaccine will be
"much lower than what you see elsewhere."
It will never be sold for a high price, ”
explains the manager.
See also
AstraZeneca and Brussels make peace
In the first nine months of the year, the group, whose serum has not yet been authorized in the United States, drew $ 2.2 billion in revenue from its vaccine (580 million doses sold worldwide )
Benefits expected in the fourth quarter with the anti-Covid vaccine should
This article is for subscribers only.
You have 70% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in